Nijmegen, Groningen, Weert (The Netherlands), & Cambridge, MA (USA) – March 3, 2020
MercachemSyncom, the leading mid-sized European drug-discovery contract research organization,
has celebrated the opening of its first office in the USA at the Cambridge Innovation Center (CIC) at One Broadway, Cambridge, MA.
Eelco Ebbers, CEO of MercachemSyncom, said: “We have seen a dramatic expansion in the past two years in our
USA discovery and development chemistry projects, with both existing and new partners, with the Boston area
being one of the key drivers. The logical conclusion was therefore to create a physical base for us in the area to
further facilitate our interactions between our current and future clients and our European operations sites.”
The office will be managed by Dr. Bart DeCorte, Vice President of Business Development for North America.
The opening of a USA base follows on from the acquisition of a further cGMP CMC drug substance development site in Weert this January.
MercachemSyncom is the leading European CRO, offering innovative chemistry, medicinal chemistry, early process
research services, and GMP production to accelerate the drug-discovery and development process in a flexible and
cost-effective way. MercachemSyncom offers integrated drug-discovery services from hit to clinic. Working for
many pharmaceutical and biotech companies throughout the world, MercachemSyncom is recognized for its high quality services and its world-class problem-solving capabilities.
More information on MercachemSyncom can be
found on the company website: www.mercachemsyncom.com.
Eelco Ebbers, CEO: +31 24 372 3300
Bart DeCorte, VP Business Development North America: +1 215 514 9668